NCT04498702: An overdue trial by Jiangsu Yahong Meditech Co., Ltd aka Asieris
This trial is overdue. It was due to report 7 years, 2 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT04498702 |
|---|---|
| Title | A Phase II Single-Arm, Open-Label, Multi-Center Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 13, 2014 |
| Completion date | Jan. 18, 2017 |
| Required reporting date | Jan. 18, 2018, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 2, 2025 |
| Days late | 2631 |